Moderate Dry Eye Syndrome Research Articles

A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients

To determine whether oral supplementation with omega-3 and omega-6 fatty acids can reduce conjunctival epithelium expression of the inflammatory marker human leucocyte antigen-DR (HLA-DR) in patients with dry eye syndrome (DES). This 3-month, double-masked, parallel-group, controlled study was conducted in nine centres, in France and Italy. Eligible adult patients with mild to moderate DES were randomized to receive a placebo containing medium-chain triglycerides or treatment supplement containing omega-3 and omega-6 fatty acids, vitamins and zinc. Treatment regimen was three capsules daily. Impression cytology (IC) was performed at baseline and at month 3 to assess the percentage of cells expressing HLA-DR and to evaluate fluorescence intensity, an alternate measure of HLA-DR. Dry eye symptoms and objective signs were also evaluated. Analyses were performed on the full analysis set (FAS) and per-protocol set (PPS). In total, 138 patients were randomized; 121 patients with available IC were included in the FAS, and of these, 106 patients had no major protocol deviations (PPS). In the PPS, there was a significant reduction in the percentage of HLA-DR-positive cells in the fatty acids group (p = 0.021). Expression of HLA-DR as measured by fluorescence intensity quantification was also significantly reduced in the fatty acids group [FAS (p = 0.041); PPS (p = 0.017)]. No significant difference was found for the signs and symptoms, but there was a tendency for improvement in patients receiving the fatty acids treatment. This study demonstrates that supplementation with omega-3 and omega-6 fatty acids can reduce expression of HLA-DR conjunctival inflammatory marker and may help improve DES symptoms.

Évaluation de l’efficacité du NAAGA dans la sécheresse oculaire

The aim of this study was to assess the efficacy of Naabak((R)) eyedrops in reducing inflammation in dry eye syndrome. This pilot, multicenter, randomized, double-blind, parallel study was carried out in adult patients suffering from moderate dry eye syndrome. Patients were treated for three months with preservative-free NAAGA (Naabak((R))) or with sodium chloride 0.9% without preservative (Larmabak(R)). They received the treatment four to six times a day during the 1(st) month and three to four times a day during the 2(nd) and 3(rd) months. At each visit (D28 and D84), clinical tests were performed as well as a biological evaluation of HLA-DR and MUC5AC expression on conjunctival imprints using flow cytometry. After three months of treatment, the ocular surface symptoms and overall discomfort were improved in patients treated with Naabak(R) and in those treated with Larmabak(R) with no significant difference between the groups. Cytological impression showed a significant decrease in the expression of inflammatory markers, notably antigen HLA-DR, in the Naabak(R) group. This study confirms the anti-inflammatory property of preservative-free NAAGA (Naabak(R)) in the context of dry eye syndrome with a similar clinical efficacy compared to sodium chloride solution (Larmabak(R)). Naabak(R) could present an additional advantage compared to artificial tears and could be indicated in the treatment of moderate inflammatory dry eye syndrome.

Staining Patterns in Dry Eye Syndrome: Rose Bengal Versus Lissamine Green

To evaluate and compare corneal staining patterns of lissamine green (LG) versus rose bengal (RB) in patients with dry eye syndrome. Secondary objectives included addressing patient's comfort after instillation and to correlate disease severity with staining patterns. Randomized, comparative, crossover series. Patients with previous diagnosis of mild to moderate dry eye syndrome were divided in 2 groups regarding dye instillation order (group A: RB first; group B: LG first). Both dyes were applied in regular intervals, and a staining score (van Bijsterveld scale) was used to correlate and compare the results. Disease severity was determined by the Ocular Surface Disease Index. Comfort was evaluated by patient's answer in an objective questionnaire. Sixty eyes of 30 consecutive patients (24 females and 6 males) were included. There was no statistical difference between groups regarding disease severity, sex, or age. LG and RB showed good clinical correlation in both groups (group A: r = 0.939, P < 0.001; group B: r = 0.915, P < 0.001). LG was better tolerated than RB (P = 0.003 in both groups). Overall, we found a low statistical correlation between disease severity and staining scores. Both LG and RB showed similar staining patterns. RB was found to provide greater patient discomfort. There was no correlation between disease severity (addressed by the ocular surface disease index questionnaire) and staining patterns (measured by the van Bijsterveld scale).

Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis

Sodium hyaluronate (SH) is used in patients with dry eye. We evaluated the efficacy and safety of SH and carboxymethylcellulose (CMC) in the treatment of dry eye syndrome with superficial keratitis. A total of 22 patients with moderate dry eye and superficial keratitis were enrolled in a prospective, randomised, masked-observer, parallel-group, single-centre study. Patients were randomly assigned to a 0.18% SH or 1% CMC solution for a 2-month period. In addition to the commonly assessed parameters in patients with dry eye (among others symptoms and corneal staining with fluorescein), flow cytometry analysis of CD44, HLA DR expressions in impression cytology was investigated as a potential efficacy parameter. Both treatments improved the symptoms and ocular surface and were well tolerated. SH significantly (p<0.05) decreased CD44 values compared with CMC. Comfort was significantly (P<0.05) better in the SH group than that in the CMC group throughout the study. Recovery in keratitis (type, extent and depth) and symptoms were faster in the SH group than in the CMC group. Blurred vision was reported by patients in the CMC group only. SH was well tolerated and tended to show a faster efficacy than did the CMC-based formulation in patients with moderate dry eye and superficial keratitis. SH could therefore advantageously be prescribed from the early stages of dry eye disease. This study also showed that flow cytometry in impression cytology specimens is a reliable tool for exploring the ocular surface at the epithelial level and that CD44, in addition to HLA DR, could be an interesting endpoint for future trials in dry eye syndrome with products based on SH.

Problems With Punctal Plugs

To the Editor. —Punctal occlusion has proved to be a valuable adjunct in the treatment of moderate to severe dry-eye syndrome. Recently, silicon plugs have become available for reversible occlusion of the lacrimal punctum and canaliculus. 1 Although this device has proved beneficial to many cases in our experience, its use is not without some potential hazard, as the following two case reports will indicate. Report of Cases. —Case 1.—A 29-year-old woman suffered from moderate dry-eye syndrome that caused irritation, particularly of the right eye. Since she was helped by temporary occlusion of her canaliculi with collagen inserts, we elected to perform punctal occlusion using a punctal plug for her lower right punctum. The lower lid was grasped with forceps in the recommended manner and the punctum was dilated with the punctal dilator supplied by the manufacturer. An attempt was then made to insert the plug, but, because of the